Stahl, SM. Enhancing outcomes from major depression: using antidepressant combination therapies with multifunctional pharmacologic mechanisms from the initiation of treatment. CNS Spectr. 2010; 15(2): 79–94.
Artigas, F, Adell, A, Celada, P. Pindolol augmentation of antidepressant response. Curr Drug Targets. 2006; 7(2): 139–147.
Nelson, JC, Papakostas, GI. Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. Am J Psychiatry. 2009; 166(9): 980–991.
Austin, MP, Mitchell, P, Goodwin, GM. Cognitive deficits in depression: possible implications for functional neuropathology. Br J Psychiatry. 2001; 178: 200–206.
Lee, RS, Hermens, DF, Porter, MA, Redoblado-Hodge, MA. A meta-analysis of cognitive deficits in first-episode major depressive disorder. J Affect Disord. 2012; 140(2): 113–124.
Mathews, A, MacLeod, C. Cognitive vulnerability to emotional disorders. Annu Rev Clin Psychol. 2005; 1: 167–195.
Hasselbalch, BJ, Knorr, U, Kessing, LV. Cognitive impairment in the remitted state of unipolar depressive disorder: a systematic review. J Affect Disord. 2011; 134(1–3): 20–31.
Naismith, SL, Longley, WA, Scott, EM, Hickie, IB. Disability in major depression related to self-rated and objectively-measured cognitive deficits: a preliminary study. BMC Psychiatry. 2007; 7: 32–38.
Altamura, CA, Mauri, MC, Ferrara, A, etal. Plasma and platelet excitatory amino acids in psychiatric disorders. Am J Psychiatry. 1993; 150(11): 1731–1733.
Kim, JS, Schmid-Burgk, W, Claus, D, Kornhuber, HH. Increased serum glutamate in depressed patients. Arch Psychiatr Nervenkr. 1982; 232(4): 299–304.
Maes, M, Verkerk, R, Vandoolaeghe, E, Lin, A, Scharpe, S. Serum levels of excitatory amino acids, serine, glycine, histidine, threonine, taurine, alanine and arginine in treatment-resistant depression: modulation by treatment with antidepressants and prediction of clinical responsivity. Acta Psychiatr Scand. 1998; 97(4): 302–308.
Levine, J, Panchalingam, K, Rapoport, A, Gershon, S, McClure, RJ, Pettegrew, JW. Increased cerebrospinal fluid glutamine levels in depressed patients. Biol Psychiatry. 2000; 47(7): 586–593.
Pangalos, MN, Malizia, AL, Francis, PT, etal. Effect of psychotropic drugs on excitatory amino acids in patients undergoing psychosurgery for depression. Br J Psychiatry. 1992; 160: 638–642.
Francis, PT, Poynton, A, Lowe, SL, etal. Brain amino acid concentrations and Ca2+-dependent release in intractable depression assessed antemortem. Brain Res. 1989; 494(2): 315–324.
Hashimoto, K, Sawa, A, Iyo, M. Increased levels of glutamate in brains from patients with mood disorders. Biol Psychiatry. 2007; 62(11): 1310–1316.
Yuksel, C, Ongur, D. Magnetic resonance spectroscopy studies of glutamate-related abnormalities in mood disorders. Biol Psychiatry. 2010; 68(9): 785–794.
Beneyto, M, Meador-Woodruff, JH. Lamina-specific abnormalities of NMDA receptor-associated postsynaptic protein transcripts in the prefrontal cortex in schizophrenia and bipolar disorder. Neuropsychopharmacology. 2008; 33(9): 2175–2186.
Beneyto, M, Kristiansen, LV, Oni-Orisan, A, McCullumsmith, RE, Meador-Woodruff, JH. Abnormal glutamate receptor expression in the medial temporal lobe in schizophrenia and mood disorders. Neuropsychopharmacology. 2007; 32(9): 1888–1902.
Bleakman, D, Alt, A, Witkin, JM. AMPA receptors in the therapeutic management of depression. CNS Neurol Disord Drug Targets. 2007; 6(2): 117–126.
Mathew, SJ, Manji, HK, Charney, DS. Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 2008; 33(9): 2080–2092.
Kendell, SF, Krystal, JH, Sanacora, G. GABA and glutamate systems as therapeutic targets in depression and mood disorders. Expert Opin Ther Targets. 2005; 9(1): 153–168.
Sanacora, G, Treccani, G, Popoli, M. Towards a glutamate hypothesis of depression: an emerging frontier of neuropsychopharmacology for mood disorders. Neuropharmacology. 2012; 62(1): 63–77.
Hashimoto, K. The role of glutamate on the action of antidepressants. Prog Neuropsychopharmacol Biol Psychiatry. 2011; 35(7): 1558–1568.
Skolnick, P, Popik, P, Trullas, R. Glutamate-based antidepressants: 20 years on. Trends Pharmacol Sci. 2009; 30(11): 563–569.
Schloss, P, Williams, DC. The serotonin transporter: a primary target for antidepressant drugs. J Psychopharmacol. 1998; 12(2): 115–121.
Smythies, J. Section V. Serotonin system. Int Rev Neurobiol. 2005; 64: 217–268.
Artigas, F. Serotonin receptors involved in antidepressant effects. Pharmacol Ther. 2013; 137(1): 119–131.
Gigliucci, V, O'Dowd, G, Casey, S, etal. Ketamine elicits sustained antidepressant-like activity via a serotonin-dependent mechanism. Psychopharmacology (Berl). 2013; 228(1): 157–166.
Nutt, DJ. Beyond psychoanaleptics—can we improve antidepressant drug nomenclature?
J Psychopharmacol. 2009; 23(4): 343–345.
Stahl, SM, Lee-Zimmerman, C, Cartwright, S, Morrissette, DA. Serotonergic drugs for depression and beyond. Curr Drug Targets. 2013; 14(5): 578–585.
Javitt, DC, Schoepp, D, Kalivas, PW, etal. Translating glutamate: from pathophysiology to treatment. Sci Transl Med. 2011; 3(102): 102mr2.
Li, N, Lee, B, Liu, RJ, etal. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science. 2010; 329(5994): 959–964.
Catena-Dell'Osso, M, Fagiolini, A, Rotella, F, Baroni, S, Marazziti, D. Glutamate system as target for development of novel antidepressants. CNS Spectr. In press.
McCarthy, DJ, Alexander, R, Smith, MA, etal. Glutamate-based depression GBD. Med Hypotheses. 2012; 78(5): 675–681.
Zarate, CA Jr, Singh, JB, Carlson, PJ, etal. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry. 2006; 63(8): 856–864.
Preskorn, SH, Baker, B, Kolluri, S, etal. An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder. J Clin Psychopharmacol. 2008; 28(6): 631–637.
Zarate, CA Jr, Singh, JB, Quiroz, JA, etal. A double-blind, placebo-controlled study of memantine in the treatment of major depression. Am J Psychiatry. 2006; 163(1): 153–155.
Anticevic, A, Gancsos, M, Murray, JD, etal. NMDA receptor function in large-scale anticorrelated neural systems with implications for cognition and schizophrenia. Proc Natl Acad Sci U S A. 2012; 109(41): 16720–16725.
Maeng, S, Zarate, CA Jr, Du, J, etal. Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors. Biol Psychiatry. 2008; 63(4): 349–352.
Tripp, A, Oh, H, Guilloux, JP, Martinowich, K, Lewis, DA, Sibille, E. Brain-derived neurotrophic factor signaling and subgenual anterior cingulate cortex dysfunction in major depressive disorder. Am J Psychiatry. 2012; 169(11): 1194–1202.
Murphy, SE, Norbury, R, O'Sullivan, U, Cowen, PJ, Harmer, CJ. Effect of a single dose of citalopram on amygdala response to emotional faces. Br J Psychiatry. 2009; 194(6): 535–540.
Norbury, R, Mackay, CE, Cowen, PJ, Goodwin, GM, Harmer, CJ. The effects of reboxetine on emotional processing in healthy volunteers: an fMRI study. Mol Psychiatry. 2008; 13(11): 1011–1020.
Knapp, RJ, Goldenberg, R, Shuck, C, etal. Antidepressant activity of memory-enhancing drugs in the reduction of submissive behavior model. Eur J Pharmacol. 2002; 440(1): 27–35.
O'Neill, MJ, Bleakman, D, Zimmerman, DM, Nisenbaum, ES. AMPA receptor potentiators for the treatment of CNS disorders. Curr Drug Targets CNS Neurol Disord. 2004; 3(3): 181–194.
Hahn, CG, Gyulai, L, Baldassano, CF, Lenox, RH. The current understanding of lamotrigine as a mood stabilizer. J Clin Psychiatry. 2004; 65(6): 791–804.
Obrocea, GV, Dunn, RM, Frye, MA, etal. Clinical predictors of response to lamotrigine and gabapentin monotherapy in refractory affective disorders. Biol Psychiatry. 2002; 51(3): 253–260.
Normann, C, Hummel, B, Scharer, LO, etal. Lamotrigine as adjunct to paroxetine in acute depression: a placebo-controlled, double-blind study. J Clin Psychiatry. 2002; 63(4): 337–344.
Zarate, CA Jr, Payne, JL, Quiroz, J, etal. An open-label trial of riluzole in patients with treatment-resistant major depression. Am J Psychiatry. 2004; 161(1): 171–174.
Sanacora, G, Kendell, SF, Fenton, L, Coric, V, Krystal, JH. Riluzole augmentation for treatment-resistant depression. Am J Psychiatry. 2004; 161(11): 2132.
Belozertseva, IV, Kos, T, Popik, P, Danysz, W, Bespalov, AY. Antidepressant-like effects of mGluR1 and mGluR5 antagonists in the rat forced swim and the mouse tail suspension tests. Eur Neuropsychopharmacol. 2007; 17(3): 172–179.
Chaki, S, Yoshikawa, R, Hirota, S, etal. MGS0039: a potent and selective group II metabotropic glutamate receptor antagonist with antidepressant-like activity. Neuropharmacology. 2004; 46(4): 457–467.
Higgins, GA, Ballard, TM, Kew, JN, etal. Pharmacological manipulation of mGlu2 receptors influences cognitive performance in the rodent. Neuropharmacology. 2004; 46(7): 907–917.
Riedel, G, Platt, B, Micheau, J. Glutamate receptor function in learning and memory. Behav Brain Res. 2003; 140(1–2): 1–47.
Teixeira, CM, Pomedli, SR, Maei, HR, Kee, N, Frankland, PW. Involvement of the anterior cingulate cortex in the expression of remote spatial memory. J Neurosci. 2006; 19(29): 7555–7564.
Homayoun, H, Stefani, MR, Adams, BW, Tamagan, GD, Moghaddam, B. Functional interaction between NMDA and mGlu5 receptors: effects on working memory, instrumental learning, motor behaviors, and dopamine release. Neuropsychopharmacology. 2004; 29(7): 1259–1269.
Moghaddam, B. Targeting metabotropic glutamate receptors for treatment of the cognitive symptoms of schizophrenia. Psychopharmacology (Berl). 2004; 174(1): 39–44.
Hamlyn, E, Brand, L, Shahid, M, Harvey, BH. The ampakine, Org 26576, bolsters early spatial reference learning and retrieval in the Morris water maze: a subchronic, dose-ranging study in rats. Behav Pharmacol. 2009; 20(7): 662–667.
Fowler, SW, Walker, JM, Klakotskaia, D, etal. Effects of a metabotropic glutamate receptor 5 positive allosteric modulator, CDPPB, on spatial learning task performance in rodents. Neurobiol Learn Mem. 2013; 99: 25–31.
Ozawa, T, Kumeji, M, Yamada, K, Ichitani, Y. D-Cycloserine enhances spatial memory in spontaneous place recognition in rats. Neurosci Lett. 2012; 509(1): 13–16.
Choi, DW, Maulucci-Gedde, M, Kriegstein, AR. Glutamate neurotoxicity in cortical cell culture. J Neurosci. 1987; 7(2): 357–368.
Zajaczkowski, W, Frankiewicz, T, Parsons, CG, Danysz, W. Uncompetitive NMDA receptor antagonists attenuate NMDA-induced impairment of passive avoidance learning and LTP. Neuropharmacology. 1997; 36(7): 961–971.
Sprouse, JS, Aghajanian, GK. Electrophysiological responses of serotoninergic dorsal raphe neurons to 5-HT1A and 5-HT1B agonists. Synapse. 1987; 1(1): 3–9.
Blier, P, de Montigny, C. Serotonin and drug-induced therapeutic responses in major depression, obsessive-compulsive and panic disorders. Neuropsychopharmacology. 1999; 21(2 suppl): 91S–98S.
El Mansari, M, Sanchez, C, Chouvet, G, Renaud, B, Haddjeri, N. Effects of acute and long-term administration of escitalopram and citalopram on serotonin neurotransmission: an in vivo electrophysiological study in rat brain. Neuropsychopharmacology. 2005; 30(7): 1269–1277.
Kennett, GA, Dourish, CT, Curzon, G. Antidepressant-like action of 5-HT1A agonists and conventional antidepressants in an animal model of depression. Eur J Pharmacol. 1987; 134(3): 265–274.
Robinson, DS, Rickels, K, Feighner, J, etal. Clinical effects of the 5-HT1A partial agonists in depression: a composite analysis of buspirone in the treatment of depression. J Clin Psychopharmacol. 1990; 10(3 suppl): 67S–76S.
Martinez, D, Hwang, D, Mawlawi, O, etal. Differential occupancy of somatodendritic and postsynaptic 5HT(1A) receptors by pindolol: a dose-occupancy study with [11C]WAY 100635 and positron emission tomography in humans. Neuropsychopharmacology. 2001; 24(3): 209–229.
Santana, N, Bortolozzi, A, Serrats, J, Mengod, G, Artigas, F. Expression of serotonin1A and serotonin2A receptors in pyramidal and GABAergic neurons of the rat prefrontal cortex. Cereb Cortex. 2004; 14(10): 1100–1109.
Aznar, S, Qian, Z, Shah, R, Rahbek, B, Knudsen, GM. The 5-HT1A serotonin receptor is located on calbindin- and parvalbumin-containing neurons in the rat brain. Brain Res. 2003; 959(1): 58–67.
Luscher, C, Jan, LY, Stoffel, M, Malenka, RC, Nicoll, RA. G protein-coupled inwardly rectifying K+ channels (GIRKs) mediate postsynaptic but not presynaptic transmitter actions in hippocampal neurons. Neuron. 1997; 19(3): 687–695.
Llado-Pelfort, L, Santana, N, Ghisi, V, Artigas, F, Celada, P. 5-HT1A receptor agonists enhance pyramidal cell firing in prefrontal cortex through a preferential action on GABA interneurons. Cereb Cortex. 2012; 22(7): 1487–1497.
Llado-Pelfort, L, Assie, MB, Newman-Tancredi, A, Artigas, F, Celada, P. Preferential in vivo action of F15599, a novel 5-HT(1A) receptor agonist, at postsynaptic 5-HT(1A) receptors. Br J Pharmacol. 2010; 160(8): 1929–1940.
Wang, S, Zhang, QJ, Liu, J, etal. The firing activity of pyramidal neurons in medial prefrontal cortex and their response to 5-hydroxytryptamine-1A receptor stimulation in a rat model of Parkinson's disease. Neuroscience. 2009; 162(4): 1091–1100.
Levkovitz, Y, Segal, M. Serotonin 5-HT1A receptors modulate hippocampal reactivity to afferent stimulation. J Neurosci. 1997; 17(14): 5591–5598.
Newman-Tancredi, A, Martel, JC, Assie, MB, etal. Signal transduction and functional selectivity of F15599, a preferential post-synaptic 5-HT1A receptor agonist. Br J Pharmacol. 2009; 156(2): 338–353.
Depoortere, R, Auclair, AL, Bardin, L, etal. F15599, a preferential post-synaptic 5-HT1A receptor agonist: activity in models of cognition in comparison with reference 5-HT1A receptor agonists. Eur Neuropsychopharmacol. 2010; 20(9): 641–654.
Meneses, A, Hong, E. 5-HT1A receptors modulate the consolidation of learning in normal and cognitively impaired rats. Neurobiol Learn Mem. 1999; 71(2): 207–218.
Herremans, AH, Hijzen, TH, Olivier, B, Slangen, JL. Serotonergic drug effects on a delayed conditional discrimination task in the rat; involvement of the 5-HT1A receptor in working memory. J Psychopharmacol. 1995; 9(3): 242–250.
Tsuji, M, Takeda, H, Matsumiya, T. Modulation of passive avoidance in mice by the 5-HT1A receptor agonist flesinoxan: comparison with the benzodiazepine receptor agonist diazepam. Neuropsychopharmacology. 2003; 28(4): 664–674.
Horiguchi, M, Meltzer, HY. The role of 5-HT1A receptors in phencyclidine (PCP)-induced novel object recognition (NOR) deficit in rats. Psychopharmacology (Berl). 2012; 221(2): 205–215.
Sari, Y. Serotonin1B receptors: from protein to physiological function and behavior. Neurosci Biobehav Rev. 2004; 28(6): 565–582.
Peddie, CJ, Davies, HA, Colyer, FM, Stewart, MG, Rodriguez, JJ. A subpopulation of serotonin 1B receptors colocalize with the AMPA receptor subunit GluR2 in the hippocampal dentate gyrus. Neurosci Lett. 2010; 485(3): 251–255.
Peddie, CJ, Davies, HA, Colyer, FM, Stewart, MG, Rodriguez, JJ. Dendritic colocalisation of serotonin1B receptors and the glutamate NMDA receptor subunit NR1 within the hippocampal dentate gyrus: an ultrastructural study. J Chem Neuroanat. 2008; 36(1): 17–26.
Cai, X, Kallarackal, AJ, Kvarta, MD, etal. Local potentiation of excitatory synapses by serotonin and its alteration in rodent models of depression. Nat Neurosci. 2013; 16(4): 464–472.
Ait, AD, Segu, L, Naili, S, Buhot, MC. Serotonin 1B receptor regulation after dorsal subiculum deafferentation. Brain Res Bull. 1995; 38(1): 17–23.
Boeijinga, PH, Boddeke, HW. Activation of 5-HT1B receptors suppresses low but not high frequency synaptic transmission in the rat subicular cortex in vitro. Brain Res. 1996; 721(1–2): 59–65.
Mlinar, B, Falsini, C, Corradetti, R. Pharmacological characterization of 5-HT(1B) receptor-mediated inhibition of local excitatory synaptic transmission in the CA1 region of rat hippocampus. Br J Pharmacol. 2003; 138(1): 71–80.
Stepien, A, Chalimoniuk, M, Strosznajder, J. Serotonin 5HT1B/1D receptor agonists abolish NMDA receptor-evoked enhancement of nitric oxide synthase activity and cGMP concentration in brain cortex slices. Cephalalgia. 1999; 19(10): 859–865.
Svenningsson, P, Chergui, K, Rachleff, I, etal. Alterations in 5-HT1B receptor function by p11 in depression-like states. Science. 2006; 311(5757): 77–80.
Tatarczynska, E, Klodzinska, A, Stachowicz, K, Chojnacka-Wojcik, E. Effects of a selective 5-HT1B receptor agonist and antagonists in animal models of anxiety and depression. Behav Pharmacol. 2004; 15(8): 523–534.
Skelin, I, Kovacevic, T, Sato, H, Diksic, M. The opposite effect of a 5-HT1B receptor agonist on 5-HT synthesis, as well as its resistant counterpart, in an animal model of depression. Brain Res Bull. 2012; 88(5): 477–486.
Redrobe, JP, MacSweeney, CP, Bourin, M. The role of 5-HT1A and 5-HT1B receptors in antidepressant drug actions in the mouse forced swimming test. Eur J Pharmacol. 1996; 318(2–3): 213–220.
Buhot, MC, Patra, SK, Naili, S. Spatial memory deficits following stimulation of hippocampal 5-HT1B receptors in the rat. Eur J Pharmacol. 1995; 285(3): 221–228.
Meneses, A. Could the 5-HT1B receptor inverse agonism affect learning consolidation?
Neurosci Biobehav Rev. 2001; 25(2): 193–201.
Eriksson, TM, Madjid, N, Elvander-Tottie, E, etal. Blockade of 5-HT 1B receptors facilitates contextual aversive learning in mice by disinhibition of cholinergic and glutamatergic neurotransmission. Neuropharmacology. 2008; 54(7): 1041–1050.
Thompson, AJ, Lummis, SC. 5-HT3 receptors. Curr Pharm Des. 2006; 12(28): 3615–3630.
Puig, MV, Santana, N, Celada, P, Mengod, G, Artigas, F. In vivo excitation of GABA interneurons in the medial prefrontal cortex through 5-HT3 receptors. Cereb Cortex. 2004; 14(12): 1365–1375.
Morales, M, Bloom, FE. The 5-HT3 receptor is present in different subpopulations of GABAergic neurons in the rat telencephalon. J Neurosci. 1997; 17(9): 3157–3167.
Reznic, J, Staubli, U. Effects of 5-HT3 receptor antagonism on hippocampal cellular activity in the freely moving rat. J Neurophysiol. 1997; 77(1): 517–521.
Ashby, CR Jr, Minabe, Y, Edwards, E, Wang, RY. 5-HT3-like receptors in the rat medial prefrontal cortex: an electrophysiological study. Brain Res. 1991; 550(2): 181–191.
Liang, X, Arvanov, VL, Wang, RY. Inhibition of NMDA-receptor mediated response in the rat medial prefrontal cortical pyramidal cells by the 5-HT3 receptor agonist SR 57227A and 5-HT: intracellular studies. Synapse. 1998; 29(3): 257–268.
Staubli, U, Xu, FB. Effects of 5-HT3 receptor antagonism on hippocampal theta rhythm, memory, and LTP induction in the freely moving rat. J Neurosci. 1995; 15(3 pt 2): 2445–2452.
Sanchez, C, Robichaud, PJ, Pehrson, A, Leiser, SC. The effects of the multimodal antidepressant Lu AA21004 on attention and vigilance measured as EEG activity in the rat. Eur Neuropsychopharmacol. 2012; 22(suppl 2): S243–S244.
Pitsikas, N, Borsini, F. Itasetron (DAU 6215) prevents age-related memory deficits in the rat in a multiple choice avoidance task. Eur J Pharmacol. 1996; 311(2–3): 115–119.
Roychoudhury, M, Kulkarni, SK. Effects of ondansetron on short-term memory retrieval in mice. Methods Find Exp Clin Pharmacol. 1997; 19(1): 43–46.
Pehrson, A, Gaarn du Jardin Nielsen, K, Jensen, JB, Sanchez, C. The novel multimodal antidepressant Lu AA21004 improves memory performance in 5-HT depleted rats via 5-HT3 and 5-HT1A receptor mechanisms. Eur Neuropsychopharmacol. 2012; 22(suppl 2): S269–S269.
Fontana, DJ, Daniels, SE, Henderson, C, Eglen, RM, Wong, EH. Ondansetron improves cognitive performance in the Morris water maze spatial navigation task. Psychopharmacology (Berl). 1995; 120(4): 409–417.
Carey, GJ, Costall, B, Domeney, AM, etal. Ondansetron and arecoline prevent scopolamine-induced cognitive deficits in the marmoset. Pharmacol Biochem Behav. 1992; 42(1): 75–83.
Martin, P, Gozlan, H, Puech, AJ. 5-HT3 receptor antagonists reverse helpless behaviour in rats. Eur J Pharmacol. 1992; 212(1): 73–78.
Mahesh, R, Bhatt, S, Devadoss, T, etal. Antidepressant potential of 5-HT3 receptor antagonist, N-n-propyl-3-ethoxyquinoxaline-2-carboxamide (6n). J Young Pharm. 2012; 4(4): 235–244.
Kos, T, Popik, P, Pietraszek, M, etal. Effect of 5-HT3 receptor antagonist MDL 72222 on behaviors induced by ketamine in rats and mice. Eur Neuropsychopharmacol. 2006; 16(4): 297–310.
Mørk, A, Pehrson, A, Tottrup, BLT, etal. Pharmacological effects of Lu AA21004: a novel multimodal compound for the treatment of major depressive disorder. J Pharmacol Exp Ther. 2012; 340(3): 666–675.
Hedlund, PB, Sutcliffe, JG. Functional, molecular and pharmacological advances in 5-HT7 receptor research. Trends Pharmacol Sci. 2004; 25(9): 481–486.
Harsing, LG Jr. The pharmacology of the neurochemical transmission in the midbrain raphe nuclei of the rat. Curr Neuropharmacol. 2006; 4(4): 313–339.
Duncan, MJ, Congleton, MR. Neural mechanisms mediating circadian phase resetting by activation of 5-HT(7) receptors in the dorsal raphe: roles of GABAergic and glutamatergic neurotransmission. Brain Res. 2010; 1366: 110–119.
Bickmeyer, U, Heine, M, Manzke, T, Richter, DW. Differential modulation of I(h) by 5-HT receptors in mouse CA1 hippocampal neurons. Eur J Neurosci. 2002; 16(2): 209–218.
Fan, LL, Zhang, QJ, Liu, J, etal. In vivo effect of 5-HT(7) receptor agonist on pyramidal neurons in medial frontal cortex of normal and 6-hydroxydopamine-lesioned rats: an electrophysiological study. Neuroscience. 2011; 190: 328–338.
Tokarski, K, Zahorodna, A, Bobula, B, Hess, G. 5-HT7 receptors increase the excitability of rat hippocampal CA1 pyramidal neurons. Brain Res. 2003; 993(1–2): 230–234.
Tokarski, K, Kusek, M, Hess, G. 5-HT7 receptors modulate GABAergic transmission in rat hippocampal CA1 area. J Physiol Pharmacol. 2011; 62(5): 535–540.
Bonaventure, P, Kelly, L, Aluisio, L, etal. Selective blockade of 5-hydroxytryptamine (5-HT)7 receptors enhances 5-HT transmission, antidepressant-like behavior, and rapid eye movement sleep suppression induced by citalopram in rodents. J Pharmacol Exp Ther. 2007; 321(2): 690–698.
Hedlund, PB. The 5-HT7 receptor and disorders of the nervous system: an overview. Psychopharmacology (Berl). 2009; 206(3): 345–354.
Stahl, SM. The serotonin-7 receptor as a novel therapeutic target. J Clin Psychiatry. 2010; 71(11): 1414–1415.
Meneses, A. Effects of the 5-HT7 receptor antagonists SB-269970 and DR 4004 in autoshaping Pavlovian/instrumental learning task. Behav Brain Res. 2004; 155(2): 275–282.
McLean, SL, Woolley, ML, Thomas, D, Neill, JC. Role of 5-HT receptor mechanisms in sub-chronic PCP-induced reversal learning deficits in the rat. Psychopharmacology (Berl). 2009; 206(3): 403–414.
Horiguchi, M, Huang, M, Meltzer, HY. The role of 5-hydroxytryptamine 7 receptors in the phencyclidine-induced novel object recognition deficit in rats. J Pharmacol Exp Ther. 2011; 338(2): 605–614.
Waters, KA, Stean, TO, Hammond, B, etal. Effects of the selective 5-HT(7) receptor antagonist SB-269970 in animal models of psychosis and cognition. Behav Brain Res. 2012; 228(1): 211–218.
Bonaventure, P, Aluisio, L, Shoblock, J, etal. Pharmacological blockade of serotonin 5-HT(7) receptor reverses working memory deficits in rats by normalizing cortical glutamate neurotransmission. PLoS One. 2011; 6(6): e20210.
Nikiforuk, A. Selective blockade of 5-HT7 receptors facilitates attentional set-shifting in stressed and control rats. Behav Brain Res. 2012; 226(1): 118–123.
Heinrich, T, Bottcher, H, Gericke, R, etal. Synthesis and structure–activity relationship in a class of indolebutylpiperazines as dual 5-HT(1A) receptor agonists and serotonin reuptake inhibitors. J Med Chem. 2004; 47(19): 4684–4692.
Page, ME, Cryan, JF, Sullivan, A, etal. Behavioral and neurochemical effects of 5-(4-[4-(5-cyano-3-indolyl)-butyl)-butyl]-1-piperazinyl)-benzofuran-2-carboxamide (EMD 68843): a combined selective inhibitor of serotonin reuptake and 5-hydroxytryptamine(1A) receptor partial agonist. J Pharmacol Exp Ther. 2002; 302(3): 1220–1227.
De Paulis, T. Drug evaluation: vilazodone—a combined SSRI and 5-HT1A partial agonist for the treatment of depression. IDrugs. 2007; 10(3): 193–201.
Guay, DR. Vilazodone hydrochloride, a combined SSRI and 5-HT1A receptor agonist for major depressive disorder. Consult Pharm. 2012; 27(12): 857–867.
Wang, SM, Han, C, Lee, SJ, Patkar, AA, Pae, CU. A review of current evidence for vilazodone in major depressive disorder. Int J Psychiatry Clin Pract. In press.
Bang-Andersen, B, Ruhland, T, Jørgensen, M, etal. Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder. J Med Chem. 2011; 54(9): 3206–3221.
Westrich, L, Pehrson, A, Zhong, H, etal. In vitro and in vivo effects of the multimodal antidepressant vortioxetine (Lu AA21004) at human and rat targets. Int J Psychiatry Clin Pract. 2012; 5(suppl 1): 47–47.
Pehrson, AL, Cremers, T, Betry, C, etal. Lu AA21004, a novel multimodal antidepressant, produces regionally selective increases of multiple neurotransmitters—a rat microdialysis and electrophysiology study. Eur Neuropsychopharmacol. 2013; 23(2): 133–145.
Bétry, C, Pehrson, AL, Etievant, A, etal. The rapid recovery of 5-HT cell firing induced by the antidepressant vortioxetine involves 5-HT3 receptor antagonism. Int J Neuropsychopharmacol. 2013; 16(5): 1115–1127.
Li, Y, Pehrson, AL, Budac, DP, Sanchez, C, Gulinello, M. A rodent model of premenstrual dysphoria: progesterone withdrawal induces depression-like behavior that is differentially sensitive to classes of antidepressants. Behav Brain Res. 2012; 234(2): 238–247.
Alvarez, E, Perez, V, Dragheim, M, Loft, H, Artigas, F. A double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorder. Int J Neuropsychopharmacol. 2012; 15(5): 589–600.
Katona, C, Hansen, T, Olsen, CK. A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder. Int Clin Psychopharmacol. 2012; 27(4): 215–223.
Baldwin, DS, Loft, H, Dragheim, M. A randomised, double-blind, placebo controlled, duloxetine-referenced, fixed-dose study of three dosages of Lu AA21004 in acute treatment of major depressive disorder (MDD). Eur Neuropsychopharmacol. 2012; 22(7): 482–491.
Baldwin, DS, Loft, H, Florea, I. Lu AA21004, a multimodal psychotropic agent, in the prevention of relapse in adult patients with generalized anxiety disorder. Int Clin Psychopharmacol. 2012; 27(4): 197–207.
Boulenger, JP, Loft, H, Florea, I. A randomized clinical study of Lu AA21004 in the prevention of relapse in patients with major depressive disorder. J Psychopharmacol. 2012; 26(11): 1408–1416.
Henigsberg, N, Mahableshwarkar, AR, Jacobsen, P, Chen, Y, Thase, ME. A randomized, double-blind, placebo-controlled 8-week trial of the efficacy and tolerability of multiple doses of Lu AA21004 in adults with major depressive disorder. J Clin Psychiatry. 2012; 73(7): 953–959.
Baldwin, DS, Hansen, T, Florea, I. Vortioxetine (Lu AA21004) in the long-term open-label treatment of major depressive disorder. Curr Med Res Opin. 2012; 28(10): 1717–1724.
Mahableshwarkar, AR, Jacobsen, PL, Chen, Y. A randomized, double-blind trial of 2.5 mg and 5 mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorder. Curr Med Res Opin. 2013; 29(3): 217–226.
Jain, R, Mahableshwarkar, AR, Jacobsen, PL, Chen, Y, Thase, ME. A randomized, double-blind, placebo-controlled 6-wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder. Int J Neuropsychopharmacol. 2013; 16(2): 313–321.
Mørk, A, Montezinho, LP, Miller, S, etal. Vortioxetine (Lu AA21004), a novel multimodal antidepressant, enhances memory in rats. Pharmacol Biochem Behav. 2013; 105C: 41–50.
Berman, RM, Cappiello, A, Anand, A, etal. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry. 2000; 47(4): 351–354.
Koliaki, CC, Messini, C, Tsolaki, M. Clinical efficacy of aniracetam, either as monotherapy or combined with cholinesterase inhibitors, in patients with cognitive impairment: a comparative open study. CNS Neurosci Ther. 2012; 18(4): 302–312.
Li, X, Tizzano, JP, Griffey, K, etal. Antidepressant-like actions of an AMPA receptor potentiator (LY392098). Neuropharmacology. 2001; 40(8): 1028–1033.
Bespalov, AY, van Gaalen, MM, Sukhotina, IA, etal. Behavioral characterization of the mGlu group II/III receptor antagonist, LY-341495, in animal models of anxiety and depression. Eur J Pharmacol. 2008; 592(1–3): 96–102.
Burgdorf, J, Zhang, XL, Nicholson, KL, etal. GLYX-13, a NMDA receptor glycine-site functional partial agonist, induces antidepressant-like effects without ketamine-like side effects. Neuropsychopharmacology. 2013; 38(5): 729–742.